TABLE 10.1 (Continued)

Summary of different applications of Gag VLPs

Application

Target

Gag sequence

Antigen/cargo

Strategy

Cell line

Animal Model

Reference

Delivery

Strategies

Nucleic Acid

delivery

M-PMV

∆ProCa-NC

AKR-targeted siRNA

Transformation

e.Coli

BL21 (DE3)

Vorácková, et al.

2014 [ 23]

Protein

Delivery

RSV Pr76gag

Gag-cre recombinase, Gag-

Fcy::Fur, and Gag-human

caspase-8, VSV-G,

truncated NA and HA,

NA-IFN-γ

TGE

HEK 293T cells

Kaczmarczyk, et al.

2011 [ 24]

Protein

Delivery

HIV-1 Pr55

Vpr1 and Vpx-2 in fusion

with SN, SN* and CAT

TGE

HeLa cells

Wu, et al. 1995 [ 34]

Drug Delivery

RSV gag-577

calcein-AM and

doxorubicin

Bacmid injection

Silkworm

BALB/c mice

Deo, et al. 2015 [ 35]

Therapeutic

Vaccines

Pancreatic

Cancer

SIVmac239 gag

Trop2

BEVS

Sf9

C57BL/6 mice

Cubas, et al.

2011 [ 36]

SIVmac239 gag

murine mesothelin

BEVS

Sf9

C57BL/6 mice

Zhang, et al.

2013 [ 37]

AKR: aldoketoreductase; BEVS: baculovirus vector expression system; CAT: chloramphenicol acetyltransferase; Gag-Fcy::Fur: Gag-Cytosine Deaminase and Uracil

Phosphory-bosyltransferase; HPV: human papilloma virus; M-PMV: Mason-Pfizer monkey virus; RSV: Rous Sarcoma Virus; SGE: stable gene expression; SIV: Simian

immunodeficiency virus; SN: staphylococcal nuclease; SN*: inactive mutant SN; TGE: transient gene expression.

244

Bioprocessing of Viral Vaccines